BioPorto A/S (CPH:BIOPOR) CFO Ole Larsen tells Proactive the diagnostic company saw "healthy growth" in revenue for the second quarter, where revenue grew by 10% to DKK (Danish Krone) 7.8 million (US$1.16 million) compared to DKK 7.2 million (US$1.08 million) in the same period in the previous year.
Larsen says the two components that drove growth included increased revenues from its NGAL test in the US, up 43% in the quarter, and increased sales of antibodies.
Price: 0.4 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE
BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen tells Proactive in its third quarter, NGAL Test revenue was up 17% compared to the same quarter last year, proving that revenue from the test has not been affected by delays caused by the coronavirus pandemic. Eriksen says what's more,...
Retail & consumer
Prev article
